Here are the 10-K annual reports from Codexis, Inc. (CDXS) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow CDXS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CDXS filings page.
Codexis, Inc. reports its 2025 annual results and strategic focus on enzymatic technologies for therapeutics manufacturing. The company recorded a net loss of $44.0 million in 2025 and had an accumulated deficit of $606.8 million as of December 31, 2025.
Codexis is pivoting around its ECO Synthesis enzymatic RNA interference (RNAi) manufacturing platform and its established small-molecule pharma biocatalysis business. The ECO Synthesis Innovation Lab now produces non‑GMP siRNA for preclinical work, with CDMO partnerships evaluating GMP-scale production and a leased GMP facility targeting Phase 1–2 supply by 2027.
In pharma biocatalysis, Codexis supplies enzymes for 18 approved drugs and 15 clinical‑stage drug candidates, while selectively pursuing only higher‑value new projects. Revenue concentration remains high, with one customer contributing about 51% of 2025 revenue. As of March 5, 2026, there were 90,869,349 common shares outstanding.